Aardvark Therapeutics Reports $14.4 Million Net Loss in Q2 2026, Faces Clinical Hold on ARD-101

Aardvark Therapeutics, Inc. reported a net loss of $14.4 million for the second quarter of 2026, slightly higher than the $14.4 million loss recorded in the same period of 2025. For the first half of 2026, the company’s net loss reached $36.0 million, compared to $23.7 million for the first half of 2025. The increase in losses is attributed to rising research and development (R&D) expenses, which totaled $27.0 million for the first six months of 2026, up from $20.9 million in the prior year. General and administrative expenses also rose significantly, amounting to $10.5 million in the first half of 2026, compared to $5.4 million in the same period of 2025.

In terms of operational changes, Aardvark has faced challenges with its lead product candidate, ARD-101, which is designed to treat hyperphagia associated with Prader-Willi Syndrome (PWS). Following a voluntary pause in clinical trials due to safety concerns, the U.S. Food and Drug Administration (FDA) placed the ARD-101 program on clinical hold in May 2026. Consequently, the company terminated its HERO and Open Label Extension trials in June 2026 and is currently evaluating the next steps for ARD-101, including potential redesigns of the clinical trials.

Aardvark's financial position showed a decrease in total assets, which fell to $81.5 million as of June 30, 2026, down from $117.2 million at the end of 2025. The company reported cash and cash equivalents of $73.8 million, an increase from $47.1 million at the end of the previous fiscal year, primarily due to the maturity and sale of short-term investments. However, total liabilities also decreased to $6.7 million from $10.5 million, reflecting a reduction in accrued liabilities and operating lease liabilities.

The company has made strategic moves to bolster its financial resources, including entering into an Equity Distribution Agreement with Piper Sandler & Co. in March 2026, allowing for the potential sale of up to $150 million in common stock. Despite these efforts, Aardvark acknowledges the need for additional capital to support ongoing operations and future development plans, particularly in light of the clinical hold on ARD-101. The company anticipates that its existing cash reserves will be sufficient to fund operations into late 2027, but it remains cautious about the uncertainties surrounding future funding and operational needs.

Looking ahead, Aardvark plans to continue its focus on developing novel therapeutics targeting metabolic diseases, while also addressing the regulatory requirements necessary to lift the clinical hold on ARD-101. The company is committed to evaluating its clinical data and engaging with the FDA to determine the best path forward for its product candidates. However, the timeline for resuming clinical trials and achieving regulatory approval remains uncertain, contingent on the resolution of the current clinical hold and the company’s ability to secure additional funding.